Overview

A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension

Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label pilot study to evaluate the safety, tolerability, and efficacy of IDN-6556 in treating portal hypertension in subjects with liver cirrhosis.
Phase:
Phase 2
Details
Lead Sponsor:
Conatus Pharmaceuticals Inc.